Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05203679Phase 2Active Not Recruiting

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Role: lead

NCT06111638Phase 2Recruiting

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Role: lead

NCT07195825Phase 1Recruiting

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

Role: lead

NCT07058662Phase 1Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

Role: collaborator

All 4 trials loaded